Seeking Alpha

Regulator delays decision on Amarin's Vascepa

  • Amarin (AMRN) says the FDA's Division of Metabolism and Endocrinology Products has delayed a decision on the reinstatement of the ANCHOR SPA.
  • There is currently "no definitive date for [a] planned response."
  • Although the company says that "based on dialogue with DMEP, [it] does not expect the delay to be for a significant period of time ... there can be no assurance that AMRN will be successful." (PR)
  • The shares, which had run up in the regular session, are down 9% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|